Overview Dividends

(AKBA) Akebia Ther - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00972D1054

Kidney Drugs, Oral HIF-PHI, Iron Phosphate, Dialysis Anemia

Biotechnology
Market Cap in USD: 411m
IPO / Inception: 2014-03-20
Return 12m vs S&P 500: -29.7%

EPS (Earnings per Share)

EPS (Earnings per Share) of AKBA over the last years for every Quarter: "2020-12": -0.6, "2021-03": -0.45, "2021-06": -0.51, "2021-09": -0.34, "2021-12": -0.4, "2022-03": -0.35, "2022-06": 0.23, "2022-09": -0.28, "2022-12": -0.04, "2023-03": -0.14, "2023-06": -0.06, "2023-09": -0.08, "2023-12": 0.0032, "2024-03": -0.09, "2024-06": -0.04, "2024-09": -0.1, "2024-12": -0.1, "2025-03": 0.0247, "2025-06": 0.0267, "2025-09": 0.002, "2025-12": 0,
EPS CAGR: 185.33%
EPS Trend: 34.0%
Last SUE: 0.94
Qual. Beats: 1

Revenue

Revenue of AKBA over the last years for every Quarter: 2020-12: 56.699, 2021-03: 52.304, 2021-06: 52.913, 2021-09: 48.756, 2021-12: 57.677, 2022-03: 61.699, 2022-06: 126.365, 2022-09: 48.714, 2022-12: 55.18, 2023-03: 40.005, 2023-06: 56.376, 2023-09: 42.046, 2023-12: 56.196, 2024-03: 32.607, 2024-06: 43.648, 2024-09: 37.428, 2024-12: 46.497, 2025-03: 57.336, 2025-06: 62.472, 2025-09: 58.766, 2025-12: null,
Rev. CAGR: 0.50%
Rev. Trend: -27.6%
Last SUE: 0.22
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 82.6%
Value at Risk 5%th 117%
Relative Tail Risk -13.64%
Reward TTM
Sharpe Ratio 0.13
Alpha -38.42
CAGR/Max DD 0.47
Character TTM
Hurst Exponent 0.220
Beta 1.071
Beta Downside 0.713
Drawdowns 3y
Max DD 63.34%
Mean DD 28.30%
Median DD 28.17%

Description: AKBA Akebia Ther December 01, 2025

Akebia Therapeutics (NASDAQ: AKBA) is a U.S. biotech focused on kidney-related diseases, developing an oral HIF-prolyl hydroxylase inhibitor (vadadustat, branded Vafseo) for anemia in both dialysis-dependent (DD) and non-dialysis-dependent (NDD) chronic kidney disease (CKD) patients, and a ferric citrate (Auryxia) to manage serum phosphorus and iron-deficiency anemia in CKD. The pipeline also includes AKB-9090 for cardiac-surgery-associated acute kidney injury and ARDS, and AKB-10108 for retinopathy of prematurity, with a commercial partnership with Mitsubishi Tanabe Pharma for Asian markets.

Key recent metrics: FY 2023 Auryxia net sales reached roughly $150 million, while the company reported a cash burn of $55 million in Q2 2024, leaving about $210 million of cash on hand. Vafseo’s Phase III program has enrolled over 1,200 patients across DD-CKD and NDD-CKD cohorts, positioning it to compete in a market projected to exceed $5 billion globally as the aging population drives CKD prevalence. The broader biotech sector is benefitting from heightened investor appetite for specialty therapeutics that address high-unmet-need chronic conditions, though pricing pressure and reimbursement uncertainty remain material risks.

If you want a data-rich, risk-adjusted assessment of AKBA’s upside, the analyst dashboard on ValueRay offers a concise, quantitative snapshot worth reviewing.

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income (-15.9m TTM) > 0 and > 6% of Revenue (6% = 13.5m TTM)
FCFTA 0.09 (>2.0%) and ΔFCFTA 27.44pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 55.52% (prev 20.26%; Δ 35.26pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.09 (>3.0%) and CFO 32.4m > Net Income -15.9m (YES >=105%, WARN >=100%)
Net Debt (-113.9m) to EBITDA (21.2m) ratio: -5.36 <= 3.0 (WARN <= 3.5)
Current Ratio 1.94 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (274.4m) change vs 12m ago 30.44% (target <= -2.0% for YES)
Gross Margin 78.85% (prev 74.19%; Δ 4.65pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 78.79% (prev 82.01%; Δ -3.22pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 0.42 (EBITDA TTM 21.2m / Interest Expense TTM 26.2m) >= 6 (WARN >= 3)

Altman Z'' -17.90

(A) 0.34 = (Total Current Assets 258.3m - Total Current Liabilities 133.4m) / Total Assets 364.2m
(B) -4.59 = Retained Earnings (Balance) -1.67b / Total Assets 364.2m
warn (B) unusual magnitude: -4.59 — check mapping/units
(C) 0.04 = EBIT TTM 10.9m / Avg Total Assets 285.6m
(D) -5.18 = Book Value of Equity -1.67b / Total Liabilities 322.6m
Total Rating: -17.90 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 59.63

1. Piotroski 5.0pt
2. FCF Yield 10.82%
3. FCF Margin 14.30%
4. Debt/Equity 1.26
5. Debt/Ebitda -5.36
6. ROIC - WACC (= -0.26)%
7. RoE -137.7%
8. Rev. Trend -27.58%
9. EPS Trend 33.96%

What is the price of AKBA shares?

As of January 09, 2026, the stock is trading at USD 1.49 with a total of 3,581,097 shares traded.
Over the past week, the price has changed by -3.87%, over one month by -8.02%, over three months by -47.72% and over the past year by -16.76%.

Is AKBA a buy, sell or hold?

Akebia Ther has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy AKBA.
  • Strong Buy: 3
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the AKBA price?

Issuer Target Up/Down from current
Wallstreet Target Price 5.4 262.4%
Analysts Target Price 5.4 262.4%
ValueRay Target Price 1.5 -0.7%

AKBA Fundamental Data Overview January 04, 2026

P/E Forward = 8.4746
P/S = 1.8275
P/B = 10.2722
Beta = 0.311
Revenue TTM = 225.1m USD
EBIT TTM = 10.9m USD
EBITDA TTM = 21.2m USD
Long Term Debt = 47.6m USD (from longTermDebt, last quarter)
Short Term Debt = 4.94m USD (from shortTermDebt, last quarter)
Debt = 52.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -113.9m USD (from netDebt column, last quarter)
Enterprise Value = 297.5m USD (411.3m + Debt 52.6m - CCE 166.4m)
Interest Coverage Ratio = 0.42 (Ebit TTM 10.9m / Interest Expense TTM 26.2m)
FCF Yield = 10.82% (FCF TTM 32.2m / Enterprise Value 297.5m)
FCF Margin = 14.30% (FCF TTM 32.2m / Revenue TTM 225.1m)
Net Margin = -7.07% (Net Income TTM -15.9m / Revenue TTM 225.1m)
Gross Margin = 78.85% ((Revenue TTM 225.1m - Cost of Revenue TTM 47.6m) / Revenue TTM)
Gross Margin QoQ = 83.49% (prev 84.12%)
Tobins Q-Ratio = 0.82 (Enterprise Value 297.5m / Total Assets 364.2m)
Interest Expense / Debt = 9.03% (Interest Expense 4.75m / Debt 52.6m)
Taxrate = 53.25% (615.0k / 1.16m)
NOPAT = 5.11m (EBIT 10.9m * (1 - 53.25%))
Current Ratio = 1.94 (Total Current Assets 258.3m / Total Current Liabilities 133.4m)
Debt / Equity = 1.26 (Debt 52.6m / totalStockholderEquity, last quarter 41.6m)
Debt / EBITDA = -5.36 (Net Debt -113.9m / EBITDA 21.2m)
Debt / FCF = -3.54 (Net Debt -113.9m / FCF TTM 32.2m)
Total Stockholder Equity = 11.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -5.57% (Net Income -15.9m / Total Assets 364.2m)
RoE = -137.7% (Net Income TTM -15.9m / Total Stockholder Equity 11.6m)
RoCE = 18.48% (EBIT 10.9m / Capital Employed (Equity 11.6m + L.T.Debt 47.6m))
RoIC = 9.05% (NOPAT 5.11m / Invested Capital 56.5m)
WACC = 9.31% (E(411.3m)/V(463.9m) * Re(9.96%) + D(52.6m)/V(463.9m) * Rd(9.03%) * (1-Tc(0.53)))
Discount Rate = 9.96% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 20.01%
[DCF Debug] Terminal Value 64.95% ; FCFF base≈32.2m ; Y1≈21.1m ; Y5≈9.66m
Fair Price DCF = 1.02 (EV 155.6m - Net Debt -113.9m = Equity 269.4m / Shares 265.4m; r=9.31% [WACC]; 5y FCF grow -40.0% → 3.0% )
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: 33.96 | EPS CAGR: 185.3% | SUE: 0.94 | # QB: 1
Revenue Correlation: -27.58 | Revenue CAGR: 0.50% | SUE: 0.22 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.01 | Chg30d=-0.025 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=0.17 | Chg30d=-0.090 | Revisions Net=+1 | Growth EPS=+325.0% | Growth Revenue=+22.4%

Additional Sources for AKBA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle